SCHEMBL6754289

SCHEMBL6754289

COc1cc(N)cc(-c2cnc(C)n2C)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.48
GSK3B P49841 1/20 0.41
DYRK1A Q13627 1/20 0.41
TTK P33981 5/20 0.39
GAA P10253 3/20 0.39
FGFR1 P11362 1/20 0.39
FGFR2 P21802 1/20 0.39
FGFR4 P22455 1/20 0.39
FGFR3 P22607 1/20 0.39
USP2 O75604 1/20 0.38
NTRK1 P04629 1/20 0.38
ALOX15 P16050 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
KIT P10721 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6760162 0.78 USP2 (0.45) MAPTGSK3BDYRK1ATTKUSP2
SCHEMBL6756618 0.78 ATP1A1 (0.40) MAPTGSK3BDYRK1AUSP2PRMT5
SCHEMBL6756596 0.76 GAA (0.41) MAPTGSK3BDYRK1ATTKGAA
SCHEMBL3311968 0.75 ATP1A1 (0.43) MAPTGSK3BDYRK1AGAAUSP2
SCHEMBL30880475 0.74 IDO1 (0.42) MAPTGSK3BDYRK1ATTKGAA
SCHEMBL6754326 0.73 MAP4K4 (0.49) MAPTDYRK1ATTKUSP2MEN1
SCHEMBL12492760 0.73 TTK (0.56) MAPTTTKUSP2TDP1PRMT5
SCHEMBL15507407 0.73 TTK (0.47) MAPTTTK
SCHEMBL30839799 0.72 ALDH1A1 (0.50) MAPTGAANTRK1TDP1KIT
SCHEMBL27185954 0.72 ALDH1A1 (0.50) MAPTGAANTRK1TDP1KIT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040087798-A1 Novel amide compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-05-06 US disclosed
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
EP-1264820-A1 NOVEL AMIDE COMPOUNDS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-12-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 MAPT 3896/4885GSK3B 2048/4885DYRK1A 3357/4885
US-20040087798-A1 Novel amide compounds H1-2, H1-0, H1-3 MAPT 3247/4885GSK3B 4671/4885DYRK1A 3409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.